mAbxience and Teva Announce Strategic Global Licensing Agreement for Oncology Biosimilar CandidateMiguel Martínez-Cava2024-04-04T14:38:15+02:00April 4, 2024|Press releases|
mAbxience and Biosidus Sign CDMO Agreement for the Manufacture of Agalsidase Beta for the Treatment of Fabry DiseaseMiguel Martínez-Cava2024-02-05T11:58:27+01:00February 5, 2024|Press releases|
mAbxience Announces Licensing Agreement with Intas Pharmaceuticals Ltd. for Etanercept Biosimilar Targeting Autoimmune Diseases in more than 150 Countries, including Europe and the United States of AmericaMiguel Martínez-Cava2023-12-20T10:49:24+01:00December 20, 2023|Press releases|
The golden era of biosimilars: patent expiration wave and their impact on global healthcareadriana.polo2025-02-20T15:42:58+01:00February 20, 2025|News|
Navigating global shifts: key takeaways from the 2025 J.P. Morgan Healthcare Conferenceadriana.polo2025-02-03T09:38:27+01:00February 3, 2025|News|
The blueprint for successful CDMO partnershipsadriana.polo2024-12-23T13:03:15+01:00December 23, 2024|News|
